Related Experiment Video

Updated: Aug 18, 2025

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke
07:00

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke

Published on: February 4, 2014

8.5K

Blockade of Kv1.3 Potassium Channel Inhibits Microglia-Mediated Neuroinflammation in Epilepsy

Xinyi Zhang1,2, Peiyu Liang1,2, Yahui Zhang1,2

  • 1Department of Pathophysiology, Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan 430071, China.

International Journal of Molecular Sciences
|December 11, 2022
PubMed

Insights

Blocking the Kv1.3 channel in microglia reduces epilepsy severity and neuronal damage. This study identifies Kv1.3 as a potential therapeutic target for epilepsy by suppressing neuroinflammation.

Area of Science:

  • Neuroscience
  • Immunology

Background:

  • Epilepsy pathophysiology involves neuroinflammation.
  • The potassium channel Kv1.3 is a potential therapeutic target in neuroinflammatory diseases.

Purpose of the Study:

  • To investigate the role of Kv1.3 in epilepsy.
  • To explore Kv1.3 as a therapeutic target for epilepsy.

Main Methods:

  • Utilized a kainic acid (KA)-induced mouse epilepsy model.
  • Administered the Kv1.3 small-molecule blocker 5-(4-phenoxybutoxy)psoralen (PAP-1).
  • Assessed seizure severity, latency, neuronal loss, microglial activation, and cytokine production, analyzing the Ca2+/NF-κB signaling pathway.

Main Results:

  • Kv1.3 was upregulated in microglia in the epilepsy model.
  • PAP-1 treatment reduced seizure severity and neuronal loss.
  • Blocking Kv1.3 suppressed microglial activation and pro-inflammatory cytokine production via the Ca2+/NF-κB pathway.

Conclusions:

  • Microglial Kv1.3 plays a critical role in epilepsy.
  • Targeting Kv1.3 with PAP-1 shows therapeutic potential for epilepsy by modulating neuroinflammation.
Keywords:
Kv1.3NF-κB signaling pathwaycalciumepilepsyinflammationmicroglia

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.6K
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

2.2K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
399
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
473
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
518
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
242
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
530
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.4K